Nanoparticles-in-film for the combined vaginal delivery of anti-HIV microbicide drugs

Cunha-Reis, Cassilda; Machado, Alexandra; Barreiros, Luísa; Araújo, Francisca; Nunes, Rui; Seabra, Vítor; Ferreira, Domingos; Segundo, Marcela A.; Sarmento, Bruno; Neves, José das

doi:10.1016/j.jconrel.2016.09.020

Cited by 88 publications

(66 citation statements)

References 71 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A few studies detailing on NPs in films as potential microbicide products have been described (Table 1.2.2). [128][129][130][131] For example, our group demonstrated the versatility and potential usefulness of NPs-in-film systems for delivering a combination of hydrophobic (efavirenz) and hydrophilic (tenofovir) antiretroviral drugs. 131 Efavirenz-loaded PLGA NPs and tenofovir were incorporated into the polymer matrix during manufacturing by solvent casting.…”

Section: Delivery Platforms For Nanomicrobicidesmentioning

confidence: 99%

“…Furthermore, NPs were found to deeply penetrate the mucosa and reach the stroma. 131 PK of efavirenz in vaginal tissue and lavage were improved when the drug was associated with NPs: relative bioavailability in tissue and lavage was increased by roughly 2 and 6 times, respectively, as compared to films containing free efavirenz (i.e., directly dispersed in the film matrix without the incorporation of NPs). All drug assays were performed using a validated liquid chromatography-tandem mass spectrometry method.…”

Section: Delivery Platforms For Nanomicrobicidesmentioning

confidence: 99%

See 1 more Smart Citation

Nanotechnologies for early diagnosis, in situ disease monitoring, and prevention

Chiu

et al. 2018

Nanotechnologies in Preventive and Regenerative Medicine

Self Cite

View full text Add to dashboard Cite

Section: Delivery Platforms For Nanomicrobicidesmentioning

confidence: 99%

Section: Delivery Platforms For Nanomicrobicidesmentioning

confidence: 99%

Nanotechnologies for early diagnosis, in situ disease monitoring, and prevention

Chiu

et al. 2018

Nanotechnologies in Preventive and Regenerative Medicine

Self Cite

View full text Add to dashboard Cite

“…The advantages of nanoparticles combine with the benefits of the films described above; examples of this are PVA films incorporating nanoparticles loaded with small interfering RNA 203. The incorporation of nanoparticles loaded with TFV or efavirenz into a film based on HPMC, PVA and glycerine was also evaluated,204 and was found to produce sustained release of the drug for 24 hours and was found to be safe at in vivo trials 205. Finally, it is worth mentioning another similar case in which PLGA nanoparticles were loaded with another antiretroviral, IQP-0528, and incorporated into a fast-dissolving film 206…”

Section: The Future Of Microbicidesmentioning

confidence: 99%

Historical development of vaginal microbicides to prevent sexual transmission of HIV in women: from past failures to future hopes

Notario-Pérez¹,

Ruíz-Caro²,

Veiga-Ochoa³

2017

DDDT

View full text Add to dashboard Cite

Infection with human immunodeficiency virus (HIV) remains a global public health concern and is particularly serious in low- and middle-income countries. Widespread sexual violence and poverty, among other factors, increase the risk of infection in women, while currently available prevention methods are outside the control of most. This has driven the study of vaginal microbicides to prevent sexual transmission of HIV from men to women in recent decades. The first microbicides evaluated were formulated as gels for daily use and contained different substances such as surfactants, acidifiers and monoclonal antibodies, which failed to demonstrate efficacy in clinical trials. A gel containing the reverse transcriptase inhibitor tenofovir showed protective efficacy in women. However, the lack of adherence by patients led to the search for dosage forms capable of releasing the active principle for longer periods, and hence to the emergence of the vaginal ring loaded with dapivirine, which requires a monthly application and is able to reduce the sexual transmission of HIV. The future of vaginal microbicides will feature the use of alternative dosage forms, nanosystems for drug release and probiotics, which have emerged as potential microbicides but are still in the early stages of development. Protecting women with vaginal microbicide formulations would, therefore, be a valuable tool for avoiding sexual transmission of HIV.

show abstract

“…Dosing amount and restrictions on dosage size could be a limitation for film dosage forms. A wide array of physicochemically diverse ARV drugs have been incorporated into films namely TFV [73, 70], DPV [17, 73, 108], EfdA [109], efavirenz [110], RC-101 [77], VRC01 anti-HIV mAb [111], and si-RNA and nanoparticles [112]. …”

Section: On-demand Vaginal Rectal and Dual Compartment Dosage Formsmentioning

confidence: 99%

“…These nanolipogels contain nanoparticles with a hydrogel-core and lipid-shell. Additionally, nanoparticles have been combined with traditional dosage forms such as gels [93] and films [110]. One of these platforms, VivaGel ™ , which is a dendrimer-based gel, has shown acceptability and high activity against HIV-1 and HSV-2 in human studies [124].…”

Section: On-demand Vaginal Rectal and Dual Compartment Dosage Formsmentioning

confidence: 99%

On-demand microbicide products: design matters

Patel

Rohan

2017

Drug Deliv. and Transl. Res.

View full text Add to dashboard Cite

Sexual intercourse (vaginal and anal) is the predominant mode of HIV (human immune deficiency virus) transmission. Topical microbicides used in an on-demand format (i.e. immediately before or after sex), can be part of an effective tool kit utilized to prevent sexual transmission of HIV. The effectiveness of prevention products is positively correlated with adherence, which is likely to depend on user acceptability of the product. The development of an efficacious and acceptable product is therefore paramount for the success of an on-demand product. Acceptability of on-demand products (e.g. gels, films, and tablets) and their attributes is influenced by a multitude of user-specific factors that span behavioral, life-style, socio-economic, and cultural aspects. In addition, physicochemical properties of the drug, anatomical and physiological aspects of anorectal and vaginal compartments, issues relating to large-scale production and cost can impact product development. These factors together with user preferences determine the design space of an effective, acceptable, and feasible on-demand product. In this review, we summarize the interacting factors that together determine product choice and its target product profile.

show abstract

Nanoparticles-in-film for the combined vaginal delivery of anti-HIV microbicide drugs

Cited by 88 publications

References 71 publications

Nanotechnologies for early diagnosis, in situ disease monitoring, and prevention

Nanotechnologies for early diagnosis, in situ disease monitoring, and prevention

Historical development of vaginal microbicides to prevent sexual transmission of HIV in women: from past failures to future hopes

On-demand microbicide products: design matters

Contact Info

Product

Resources

About